Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
← catalyst calendarNCT07493304 · readout in 1,784 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,600estimated
Sites
6
Countries
South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2031-07-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-07-08 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Thromboembolism (VTE)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: Apixaban
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment-Emergent Adverse Events (TEAEs)
measured Approximately 6 months
Severity of TEAEs
measured Approximately 6 months
Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]
measured Up to approximately 3.5 years
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
measured Up to approximately 3.5 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed